Product: Phospho-STAT3 (Tyr705) Antibody
Catalog: AF3293
Description: Rabbit polyclonal antibody to Phospho-STAT3 (Tyr705)
Application: WB IHC IF/ICC IP
Reactivity: Human, Mouse, Rat
Prediction: Pig, Zebrafish, Bovine, Horse, Sheep, Rabbit, Chicken
Mol.Wt.: 86kDa; 88kD(Calculated).
Uniprot: P40763
RRID: AB_2810278

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200, IP, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Pig(100%), Zebrafish(100%), Bovine(100%), Horse(100%), Sheep(91%), Rabbit(100%), Chicken(100%)
Clonality:
Polyclonal
Specificity:
Phospho-STAT3 (Tyr705) Antibody detects endogenous levels of STAT3 only when phosphorylated at Tyrosine 705.
RRID:
AB_2810278
Cite Format: Affinity Biosciences Cat# AF3293, RRID:AB_2810278.
Conjugate:
Unconjugated.
Purification:
The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho-peptide and non-phospho-peptide affinity columns.
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

1110034C02Rik; Acute Phase Response Factor; Acute-phase response factor; ADMIO; APRF; AW109958; DNA binding protein APRF; FLJ20882; HIES; MGC16063; Signal transducer and activator of transcription 3 (acute phase response factor); Signal transducer and activator of transcription 3; STAT 3; Stat3; STAT3_HUMAN;

Immunogens

Immunogen:
Uniprot:
Gene(ID):
Expression:
P40763 STAT3_HUMAN:

Heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas.

Description:
The protein encoded by this gene is a member of the STAT protein family. In response to cytokines and growth factors, STAT family members are phosphorylated by the receptor associated kinases, and then form homo- or heterodimers that translocate to the cell nucleus where they act as transcription activators.
Sequence:
MAQWNQLQQLDTRYLEQLHQLYSDSFPMELRQFLAPWIESQDWAYAASKESHATLVFHNLLGEIDQQYSRFLQESNVLYQHNLRRIKQFLQSRYLEKPMEIARIVARCLWEESRLLQTAATAAQQGGQANHPTAAVVTEKQQMLEQHLQDVRKRVQDLEQKMKVVENLQDDFDFNYKTLKSQGDMQDLNGNNQSVTRQKMQQLEQMLTALDQMRRSIVSELAGLLSAMEYVQKTLTDEELADWKRRQQIACIGGPPNICLDRLENWITSLAESQLQTRQQIKKLEELQQKVSYKGDPIVQHRPMLEERIVELFRNLMKSAFVVERQPCMPMHPDRPLVIKTGVQFTTKVRLLVKFPELNYQLKIKVCIDKDSGDVAALRGSRKFNILGTNTKVMNMEESNNGSLSAEFKHLTLREQRCGNGGRANCDASLIVTEELHLITFETEVYHQGLKIDLETHSLPVVVISNICQMPNAWASILWYNMLTNNPKNVNFFTKPPIGTWDQVAEVLSWQFSSTTKRGLSIEQLTTLAEKLLGPGVNYSGCQITWAKFCKENMAGKGFSFWVWLDNIIDLVKKYILALWNEGYIMGFISKERERAILSTKPPGTFLLRFSESSKEGGVTFTWVEKDISGKTQIQSVEPYTKQQLNNMSFAEIIMGYKIMDATNILVSPLVYLYPDIPKEEAFGKYCRPESQEHPEADPGSAAPYLKTKFICVTPTTCSNTIDLPMSPRTLDSLMQFGNNGEGAEPSAGGQFESLTFDMELTSECATSPM

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Horse
100
Bovine
100
Zebrafish
100
Chicken
100
Rabbit
100
Sheep
91
Dog
0
Xenopus
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P40763 As Substrate

Site PTM Type Enzyme
A2 Acetylation
S25 Phosphorylation
Y45 Phosphorylation
K49 Acetylation
K49 Methylation
Y68 Phosphorylation
Y79 Phosphorylation
K87 Acetylation
K87 Ubiquitination
K97 Ubiquitination
K140 Ubiquitination
K153 Ubiquitination
K161 Ubiquitination
K163 Ubiquitination
Y176 Phosphorylation
K177 Sumoylation
K177 Ubiquitination
K180 Ubiquitination
S181 Phosphorylation
S194 Phosphorylation
T196 Phosphorylation
K199 Ubiquitination
T236 Phosphorylation
K244 Ubiquitination
K283 Ubiquitination
K290 Ubiquitination
K294 Ubiquitination
K318 Ubiquitination
K348 Ubiquitination
K363 Ubiquitination
K365 Ubiquitination
K370 Acetylation
K370 Ubiquitination
K383 Ubiquitination
K409 Ubiquitination
S429 Phosphorylation
T440 Phosphorylation
Y446 Phosphorylation
K451 Sumoylation
K495 Sumoylation
Y539 Phosphorylation
S540 Phosphorylation
K551 Ubiquitination
K574 Ubiquitination
K601 Acetylation
K601 Ubiquitination
T605 Phosphorylation
K615 Acetylation
K615 Ubiquitination
K626 Ubiquitination
K631 Acetylation
K631 Ubiquitination
T632 Phosphorylation
S636 Phosphorylation
Y640 Phosphorylation
T641 Phosphorylation
K642 Ubiquitination
Y674 Phosphorylation
K679 Ubiquitination
K685 Acetylation
K685 Ubiquitination
Y686 Phosphorylation
S691 Phosphorylation
S701 Phosphorylation
Y705 Phosphorylation O60674 (JAK2) , Q15300 (RET/PTC2) , P23458 (JAK1) , P22455 (FGFR4) , P27361 (MAPK3) , Q13882 (PTK6) , P22607 (FGFR3) , Q9UM73 (ALK) , P14618 (PKM) , P16591 (FER) , P12931 (SRC)
K707 Acetylation
K707 Ubiquitination
T708 Phosphorylation
T714 Phosphorylation
T717 Phosphorylation
S719 Phosphorylation
T721 Phosphorylation
S727 Phosphorylation P51812 (RPS6KA3) , P45984-2 (MAPK9) , Q13233 (MAP3K1) , O75582 (RPS6KA5) , P28482 (MAPK1) , Q13555 (CAMK2G) , O43293 (DAPK3) , P42345 (MTOR) , P27361 (MAPK3) , Q02156 (PRKCE) , P45983 (MAPK8) , P51617 (IRAK1) , Q16539 (MAPK14) , Q05655 (PRKCD) , Q9UBE8 (NLK) , P06493 (CDK1) , Q00535 (CDK5) , Q9HC98 (NEK6)
S754 Phosphorylation

Research Backgrounds

Function:

Signal transducer and transcription activator that mediates cellular responses to interleukins, KITLG/SCF, LEP and other growth factors. Once activated, recruits coactivators, such as NCOA1 or MED1, to the promoter region of the target gene. May mediate cellular responses to activated FGFR1, FGFR2, FGFR3 and FGFR4. Binds to the interleukin-6 (IL-6)-responsive elements identified in the promoters of various acute-phase protein genes. Activated by IL31 through IL31RA. Acts as a regulator of inflammatory response by regulating differentiation of naive CD4(+) T-cells into T-helper Th17 or regulatory T-cells (Treg): deacetylation and oxidation of lysine residues by LOXL3, leads to disrupt STAT3 dimerization and inhibit its transcription activity. Involved in cell cycle regulation by inducing the expression of key genes for the progression from G1 to S phase, such as CCND1. Mediates the effects of LEP on melanocortin production, body energy homeostasis and lactation (By similarity). May play an apoptotic role by transctivating BIRC5 expression under LEP activation. Cytoplasmic STAT3 represses macroautophagy by inhibiting EIF2AK2/PKR activity. Plays a crucial role in basal beta cell functions, such as regulation of insulin secretion (By similarity).

PTMs:

Tyrosine phosphorylated upon stimulation with EGF. Tyrosine phosphorylated in response to constitutively activated FGFR1, FGFR2, FGFR3 and FGFR4 (By similarity). Activated through tyrosine phosphorylation by BMX. Tyrosine phosphorylated in response to IL6, IL11, LIF, CNTF, KITLG/SCF, CSF1, EGF, PDGF, IFN-alpha, LEP and OSM. Activated KIT promotes phosphorylation on tyrosine residues and subsequent translocation to the nucleus. Phosphorylated on serine upon DNA damage, probably by ATM or ATR. Serine phosphorylation is important for the formation of stable DNA-binding STAT3 homodimers and maximal transcriptional activity. ARL2BP may participate in keeping the phosphorylated state of STAT3 within the nucleus. Upon LPS challenge, phosphorylated within the nucleus by IRAK1. Upon erythropoietin treatment, phosphorylated on Ser-727 by RPS6KA5. Phosphorylation at Tyr-705 by PTK6 or FER leads to an increase of its transcriptional activity. Dephosphorylation on tyrosine residues by PTPN2 negatively regulates IL6/interleukin-6 signaling.

Acetylated on lysine residues by CREBBP. Deacetylation by LOXL3 leads to disrupt STAT3 dimerization and inhibit STAT3 transcription activity. Oxidation of lysine residues to allysine on STAT3 preferentially takes place on lysine residues that are acetylated.

Some lysine residues are oxidized to allysine by LOXL3, leading to disrupt STAT3 dimerization and inhibit STAT3 transcription activity. Oxidation of lysine residues to allysine on STAT3 preferentially takes place on lysine residues that are acetylated.

(Microbial infection) Phosphorylated on Tyr-705 in the presence of S.typhimurium SarA.

S-palmitoylated by ZDHHC19 in SH2 putative lipid-binding pockets, leading to homodimerization. Nuclear STAT3 is highly palmitoylated (about 75%) compared with cytoplasmic STAT3 (about 20%).

S-stearoylated, probably by ZDHHC19.

Subcellular Location:

Cytoplasm. Nucleus.
Note: Shuttles between the nucleus and the cytoplasm. Translocated into the nucleus upon tyrosine phosphorylation and dimerization, in response to signaling by activated FGFR1, FGFR2, FGFR3 or FGFR4. Constitutive nuclear presence is independent of tyrosine phosphorylation. Predominantly present in the cytoplasm without stimuli. Upon leukemia inhibitory factor (LIF) stimulation, accumulates in the nucleus. The complex composed of BART and ARL2 plays an important role in the nuclear translocation and retention of STAT3. Identified in a complex with LYN and PAG1.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas.

Subunit Structure:

Forms a homodimer or a heterodimer with a related family member (at least STAT1). Interacts with IL31RA, NCOA1, PELP1, SIPAR, SOCS7, STATIP1 and TMF1 (By similarity). Interacts with IL23R in presence of IL23. Interacts (via SH2 domain) with NLK. Interacts with ARL2BP; the interaction is enhanced by LIF and JAK1 expression (By similarity). Interacts with KPNA4 and KPNA5; KPNA4 may be the primary mediator of nuclear import (By similarity). Interacts with CAV2; the interaction is increased on insulin-induced tyrosine phosphorylation of CAV2 and leads to STAT3 activation (By similarity). Interacts with ARL2BP; interaction is enhanced with ARL2. Interacts with NEK6 (By similarity). Binds to CDK9 when activated and nuclear. Interacts with BMX. Interacts with ZIPK/DAPK3. Interacts with PIAS3; the interaction occurs on stimulation by IL6, CNTF or OSM and inhibits the DNA binding activity of STAT3. In prostate cancer cells, interacts with STAT3 and promotes DNA binding activity of STAT3. Interacts with STMN3, antagonizing its microtubule-destabilizing activity. Interacts with the 'Lys-129' acetylated form of BIRC5/survivin. Interacts with FER. Interacts (via SH2 domain) with EIF2AK2/PKR (via the kinase catalytic domain). Interacts with STAT3; the interaction is independent of STAT3 Tyr-705 phosphorylation status. Interacts with FGFR4. Interacts with OCAD1 (By similarity). Interacts with ZDHHC19, leading to palmitoylation which promotes homodimerization and activation.

(Microbial infection) Interacts with HCV core protein.

(Microbial infection) Interacts with S.typhimurium SarA.

Family&Domains:

Belongs to the transcription factor STAT family.

Research Fields

· Cellular Processes > Cell growth and death > Necroptosis.   (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Signaling pathways regulating pluripotency of stem cells.   (View pathway)

· Environmental Information Processing > Signal transduction > HIF-1 signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > FoxO signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Jak-STAT signaling pathway.   (View pathway)

· Human Diseases > Drug resistance: Antineoplastic > EGFR tyrosine kinase inhibitor resistance.

· Human Diseases > Endocrine and metabolic diseases > Insulin resistance.

· Human Diseases > Infectious diseases: Parasitic > Toxoplasmosis.

· Human Diseases > Infectious diseases: Viral > Hepatitis C.

· Human Diseases > Infectious diseases: Viral > Hepatitis B.

· Human Diseases > Infectious diseases: Viral > Measles.

· Human Diseases > Infectious diseases: Viral > Epstein-Barr virus infection.

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Viral carcinogenesis.

· Human Diseases > Cancers: Overview > Proteoglycans in cancer.

· Human Diseases > Cancers: Overview > MicroRNAs in cancer.

· Human Diseases > Cancers: Specific types > Pancreatic cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Acute myeloid leukemia.   (View pathway)

· Human Diseases > Cancers: Specific types > Non-small cell lung cancer.   (View pathway)

· Human Diseases > Immune diseases > Inflammatory bowel disease (IBD).

· Organismal Systems > Immune system > Chemokine signaling pathway.   (View pathway)

· Organismal Systems > Immune system > Th17 cell differentiation.   (View pathway)

· Organismal Systems > Endocrine system > Prolactin signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Adipocytokine signaling pathway.

References

1). Gut dysbiosis promotes prostate cancer progression and docetaxel resistance via activating NF-κB-IL6-STAT3 axis. Microbiome (PubMed: 35710492) [IF=15.5]

Application: IF/ICC    Species: Mouse    Sample: tumor tissue

Fig. 3 Intratumoral LPS activated NF-κB-IL6-STAT3 axis. A LPS levels in mouse feces and serum by ELISA; HE staining (scale bar, 50 μm) and histology score for colon tissue in the Abx and NC group. B Immunohistochemistry (scale bar, 50 μm) for LPS in subcutaneous and orthotopic tumor tissues and western blot of intratumoral LPS levels from three biological duplications for the Abx and NC group. C Transcription levels of cytokines by RT-qPCR and protein levels of IL6 in cell supernatant by ELISA in RM-1 cultured with LPS (100 μg/ml) for 24 h. D, E Immunofluorescence (scale bar, 100 μm) for p-p65 and p-STAT3 in RM-1 cultured with or without LPS for 24 h; western blot of relative proteins for RM-1 cultured with LPS at different concentrations for 24 h; transcription levels of IL6 by RT-qPCR and western blot of relative proteins in RM-1 cultured with LPS or LPS with BAY-11-7082 for 24 h; protein levels of p-STAT3 and STAT3 in RM-1 cultured with CM or CM with antibody-IL6 for 24 h. F, G IL6 levels in tumor tissue lysate and serum by ELISA. Western blot of relative proteins in tumor from three biological duplications. Immunohistochemistry of tumor tissues for p-p65- and p-STAT3-positive cell (scale bar, 50 μm). Statistical significance was assessed by unpaired Student’s T-test or LSD in one-way ANOVA. *p < 0.05, **p < 0.01, and ***p < 0.001: compared to the NC group; #p < 0.05, ##p < 0.01, and ###p < 0.001: compared to the LPS or CM group

Application: WB    Species: Mouse    Sample: tumor tissue

Fig. 3 Intratumoral LPS activated NF-κB-IL6-STAT3 axis. A LPS levels in mouse feces and serum by ELISA; HE staining (scale bar, 50 μm) and histology score for colon tissue in the Abx and NC group. B Immunohistochemistry (scale bar, 50 μm) for LPS in subcutaneous and orthotopic tumor tissues and western blot of intratumoral LPS levels from three biological duplications for the Abx and NC group. C Transcription levels of cytokines by RT-qPCR and protein levels of IL6 in cell supernatant by ELISA in RM-1 cultured with LPS (100 μg/ml) for 24 h. D, E Immunofluorescence (scale bar, 100 μm) for p-p65 and p-STAT3 in RM-1 cultured with or without LPS for 24 h; western blot of relative proteins for RM-1 cultured with LPS at different concentrations for 24 h; transcription levels of IL6 by RT-qPCR and western blot of relative proteins in RM-1 cultured with LPS or LPS with BAY-11-7082 for 24 h; protein levels of p-STAT3 and STAT3 in RM-1 cultured with CM or CM with antibody-IL6 for 24 h. F, G IL6 levels in tumor tissue lysate and serum by ELISA. Western blot of relative proteins in tumor from three biological duplications. Immunohistochemistry of tumor tissues for p-p65- and p-STAT3-positive cell (scale bar, 50 μm). Statistical significance was assessed by unpaired Student’s T-test or LSD in one-way ANOVA. *p < 0.05, **p < 0.01, and ***p < 0.001: compared to the NC group; #p < 0.05, ##p < 0.01, and ###p < 0.001: compared to the LPS or CM group

Application: IHC    Species: Mouse    Sample: tumor tissue

Fig. 3 Intratumoral LPS activated NF-κB-IL6-STAT3 axis. A LPS levels in mouse feces and serum by ELISA; HE staining (scale bar, 50 μm) and histology score for colon tissue in the Abx and NC group. B Immunohistochemistry (scale bar, 50 μm) for LPS in subcutaneous and orthotopic tumor tissues and western blot of intratumoral LPS levels from three biological duplications for the Abx and NC group. C Transcription levels of cytokines by RT-qPCR and protein levels of IL6 in cell supernatant by ELISA in RM-1 cultured with LPS (100 μg/ml) for 24 h. D, E Immunofluorescence (scale bar, 100 μm) for p-p65 and p-STAT3 in RM-1 cultured with or without LPS for 24 h; western blot of relative proteins for RM-1 cultured with LPS at different concentrations for 24 h; transcription levels of IL6 by RT-qPCR and western blot of relative proteins in RM-1 cultured with LPS or LPS with BAY-11-7082 for 24 h; protein levels of p-STAT3 and STAT3 in RM-1 cultured with CM or CM with antibody-IL6 for 24 h. F, G IL6 levels in tumor tissue lysate and serum by ELISA. Western blot of relative proteins in tumor from three biological duplications. Immunohistochemistry of tumor tissues for p-p65- and p-STAT3-positive cell (scale bar, 50 μm). Statistical significance was assessed by unpaired Student’s T-test or LSD in one-way ANOVA. *p < 0.05, **p < 0.01, and ***p < 0.001: compared to the NC group; #p < 0.05, ##p < 0.01, and ###p < 0.001: compared to the LPS or CM group

2). A Bioinspired Manganese-Organic Framework Ameliorates Ischemic Stroke through its Intrinsic Nanozyme Activity and Upregulating Endogenous Antioxidant Enzymes. Advanced Science (PubMed: 37129343) [IF=15.1]

Application: WB    Species: Mouse    Sample: N2a cells

Figure 3 The effect of pDA-MNOF on upregulating HO1 and SOD2 via STAT3 signaling. a) Western blot analysis of p-STAT3, STAT3, HO1, and SOD2 expression in N2a cells treated with 12.5 µg mL−1 pDA-MNOF for various time durations. b) Quantification of the band intensity ratios of p-STAT3/STAT3, HO1/β-actin, and SOD2/β-actin in (a). t-STAT3 indicated total proteins of p-STAT3 and STAT3. c) Quantification of fluorescent intensity of p-STAT3, HO1, and SOD2 in PBS or 12.5 µg mL−1 pDA-MNOF-treated N2a cells (n = 4). Data were presented with mean ± s.d.; *, p < 0.05; **, p < 0.01; T-test. d) Representative images of immunofluorescent staining for p-STAT3, HO-1, and SOD-2 (red) in indicated groups. Nuclei were stained in blue, and cell body was outlined with white dashed lines. Scale bar, 20 µm. e) Western blot analysis of p-STAT3, STAT3, HO1, and SOD2 expression in N2a cells treated with different concentrations of pDA-MNOF for 12 h. f) Quantification of the band intensity ratios of p-STAT3/STAT3, HO1/β-actin, and SOD2/β-actin in (e). g) Experimental scheme for the RNA interference and pathway inhibition assays. h) Western blot analysis of p-STAT3 and STAT3 in N2a cells treated with PBS, siRNA Control (siRNA Ctrl), siRNA 1#, siRNA 2#, and siRNA 3#. i) Quantification of the band intensity ratios of p-STAT3/β-actin and STAT3/β-actin in (h). j) N2a cells were transfected with siRNA Ctrl, siRNA 2#, and siRNA 3#, followed by treatment with pDA-MNOF; the lysates were analyzed with indicated antibodies. k) Quantification of the band intensity ratios of p-STAT3/β-actin, HO1/β-actin, and SOD2/β-actin in (j). Data were presented with mean ± s.d.; *, p < 0.05; ANOVA. l) N2a cells were treated with PBS or pDA-MNOF, followed by treatment with AG490; the lysates were analyzed with indicated antibodies. m) Quantification of the band intensity ratios of p-STAT3/STAT3, HO1/β-actin, and SOD2/β-actin in (l) (n = 3).

3). Aligned electrospun poly(l-lactide) nanofibers facilitate wound healing by inhibiting macrophage M1 polarization via the JAK-STAT and NF-κB pathways. JOURNAL OF NANOBIOTECHNOLOGY (PubMed: 35883095) [IF=10.2]

Application: WB    Species: Mice    Sample:

Fig. 3 The underlying mechanism by which aligned fibers affected macrophage polarization. A Venn diagram showing differentially expressed genes. B KEGG pathway analysis between the A20 and R20 groups. C Heatmap of differentially expressed genes among the three groups. D Heatmap of macrophage polarization-related genes between the A20 and R20 groups. E Volcano diagram of differentially expressed genes. F Western blot analysis of the NF-κB signaling pathway. G Immunofluorescence staining showing the nuclear translocation of NF-κB p65. The nucleus is stained blue, and NF-κB p65 protein is stained red. H Western blot images and semiquantitative analysis of the JAK-STAT signaling pathway (*p < 0.05, **p < 0.01, n = 3)

4). P21 and P27 promote tumorigenesis and progression via cell cycle acceleration in seminal vesicles of TRAMP mice. International Journal of Biological Sciences (PubMed: 31592235) [IF=9.2]

5). Protopanaxadiol inhibits epithelial-mesenchymal transition of hepatocellular carcinoma by targeting STAT3 pathway. Cell Death & Disease (PubMed: 31431619) [IF=9.0]

Application: WB    Species: human    Sample: PLC/PRF/5 cells

Fig. 4| PPD inhibited EMT of HCC cells by targeting STAT3. a Molecular docking scores for PPD and six potential targets. b Predicted model of PPD binding to the SH2 domain of STAT3 as shown by computational docking. The protein backbone is portrayed as a transparent green ribbon, and PPD is depicted as atom-red sticks-and-balls. c Biacore analysis results of PPD and STAT3. d, e PPD inhibited the translocation of STAT3 to the nucleus in PLC/PRF/5 cells detected by immunofluorescence and Western blot

6). DINP aggravates autoimmune thyroid disease through activation of the Akt/mTOR pathway and suppression of autophagy in Wistar rats. ENVIRONMENTAL POLLUTION (PubMed: 30447474) [IF=8.9]

7). Acid sphingomyelinase downregulation alleviates vascular endothelial leptin resistance in rats. ACTA PHARMACOLOGICA SINICA (PubMed: 31848475) [IF=8.2]

Application: WB    Species: Rat    Sample: rat aortic endothelial cells (RAECs)

Fig. 1 ASM downregulation improved PA-induced leptin resistance in RAECs. Western blot gels and summarized data showing the protein expression of Ob-Rb (a) and SOCS3 (b) in RAECs treated with PA (0.1, 0.2, and 0.3 mM) with or without 100 nM leptin. RAECs were incubated with 0.3 mM PA for 24 h and were then transfected with ASM siRNA for 24 h. Then, 100 nM leptin was added for 15 min prior to the collection of the cells. Then, Western blotting and an AmpliteTM Fluorimetric Kit were used to test the protein expression of ASM (c) and ASM activity (d), respectively, in RAECs. Representative fluorescence images (e, scale bar = 20 μm) and summarized data showing the mean fluorescent intensity (MFI) of a FITC-labeled anti-ceramide antibody (f). The photographs were taken at ×400 magnification. The protein expression of ObRb (g) and SOCS3 (h) and the ratio of p-STAT3/STAT3 (i) was determined using Western blotting. The data are the means ± SEMs from three experiments. *P < 0.05 vs. scramble control (Scr Ctrl); #P < 0.05 vs. the PA alone-treated group

8). Panax notoginseng saponins alleviates inflammation induced by microglial activation and protects against ischemic brain injury via inhibiting HIF-1α/PKM2/STAT3 signaling. BIOMEDICINE & PHARMACOTHERAPY (PubMed: 36271540) [IF=7.5]

9). CXCL5, the upregulated chemokine in patients with uterine cervix cancer, in vivo and in vitro contributes to oncogenic potential of Hela uterine cervix cancer cells. BIOMEDICINE & PHARMACOTHERAPY (PubMed: 30257367) [IF=7.5]

10). Formononetin protects against inflammation associated with cerebral ischemia-reperfusion injury in rats by targeting the JAK2/STAT3 signaling pathway. BIOMEDICINE & PHARMACOTHERAPY (PubMed: 35339827) [IF=7.5]

Load more

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.